Business Description
Virbac SA
ISIN : FR0000031577
Compare
Compare
Traded in other countries / regions
VIRP.France0NM7.UKV16.GermanyVRBCF.USA IPO Date
1989-07-27Description
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, followed by Asia and Latin America.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.39 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.41 | |||||
| Debt-to-EBITDA | 1.5 | |||||
| Interest Coverage | 21.21 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.96 | |||||
| Beneish M-Score | -2.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.1 | |||||
| 3-Year EBITDA Growth Rate | -1.6 | |||||
| 3-Year EPS without NRI Growth Rate | 9.2 | |||||
| 3-Year FCF Growth Rate | -13.2 | |||||
| 3-Year Book Growth Rate | 13.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 15.47 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 7.72 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.18 | |||||
| 9-Day RSI | 35.7 | |||||
| 14-Day RSI | 39.26 | |||||
| 6-1 Month Momentum % | 10.37 | |||||
| 12-1 Month Momentum % | 41.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.65 | |||||
| Quick Ratio | 0.89 | |||||
| Cash Ratio | 0.3 | |||||
| Days Inventory | 294 | |||||
| Days Sales Outstanding | 51.39 | |||||
| Days Payable | 117.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.38 | |||||
| Dividend Payout Ratio | 0.08 | |||||
| Forward Dividend Yield % | 0.38 | |||||
| 5-Year Yield-on-Cost % | 0.38 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | -3.47 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 66.38 | |||||
| Operating Margin % | 16.93 | |||||
| Net Margin % | 10.52 | |||||
| FCF Margin % | 5.52 | |||||
| ROE % | 15.14 | |||||
| ROA % | 9.05 | |||||
| ROIC % | 14.67 | |||||
| 3-Year ROIIC % | 10.33 | |||||
| ROC (Joel Greenblatt) % | 37.88 | |||||
| ROCE % | 19.37 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21.09 | |||||
| Forward PE Ratio | 17.66 | |||||
| PE Ratio without NRI | 21.45 | |||||
| Shiller PE Ratio | 41.01 | |||||
| Price-to-Owner-Earnings | 27.94 | |||||
| PEG Ratio | 1.57 | |||||
| PS Ratio | 2.23 | |||||
| PB Ratio | 2.99 | |||||
| Price-to-Tangible-Book | 5.89 | |||||
| Price-to-Free-Cash-Flow | 40.37 | |||||
| Price-to-Operating-Cash-Flow | 21.52 | |||||
| EV-to-EBIT | 14.55 | |||||
| EV-to-EBITDA | 11.77 | |||||
| EV-to-Revenue | 2.36 | |||||
| EV-to-FCF | 43.52 | |||||
| Price-to-Projected-FCF | 1.75 | |||||
| Price-to-Median-PS-Value | 1.25 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.81 | |||||
| Price-to-Graham-Number | 2.35 | |||||
| Price-to-Net-Current-Asset-Value | 38.71 | |||||
| Earnings Yield (Greenblatt) % | 6.87 | |||||
| FCF Yield % | 2.54 | |||||
| Forward Rate of Return (Yacktman) % | 16.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Virbac SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,339.365 | ||
| EPS (TTM) (€) | 16.83 | ||
| Beta | 0.84 | ||
| Volatility % | 30.66 | ||
| 14-Day RSI | 39.26 | ||
| 14-Day ATR (€) | 10.777802 | ||
| 20-Day SMA (€) | 367.4 | ||
| 12-1 Month Momentum % | 41.33 | ||
| 52-Week Range (€) | 269.5 - 400 | ||
| Shares Outstanding (Mil) | 8.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Virbac SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Virbac SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Virbac SA Frequently Asked Questions
What is Virbac SA(XPAR:VIRP)'s stock price today?
The current price of XPAR:VIRP is €348.00. The 52 week high of XPAR:VIRP is €400.00 and 52 week low is €269.50.
When is next earnings date of Virbac SA(XPAR:VIRP)?
The next earnings date of Virbac SA(XPAR:VIRP) is .
Does Virbac SA(XPAR:VIRP) pay dividends? If so, how much?
The Dividend Yield %  of Virbac SA(XPAR:VIRP) is 0.38% (As of Today), Highest Dividend Payout Ratio of Virbac SA(XPAR:VIRP) was 1.93. The lowest was 0.05. And the median was 0.09. The  Forward Dividend Yield % of Virbac SA(XPAR:VIRP) is 0.38%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers